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Impact of bronchiectasis on 
outcomes of hospitalized patients 
with acute exacerbation of chronic 
obstructive pulmonary disease: A 
propensity matched analysis
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Albert Gabarrús2, Néstor Soler2, Alfredo Chetta1 & Antoni Torres2
The coexistence of both Chronic Obstructive Pulmonary Disease (COPD) and bronchiectasis (BE) define 
an emerging phenotype with a worse prognosis; however, data about these patients do not consider 
baseline characteristics as confounders. We evaluate the impact of BE on outcomes of hospitalized 
patients with acute exacerbation of COPD (AECOPD). We prospectively considered AECOPD patients, 
analysed using a propensity score matching (PSM) method. The outcomes included length of hospital 
stay, use of non-invasive and invasive mechanical ventilation, intensive care unit admission, and 
mortality up to 3-years. Out of the 449 patients enrolled, 160 had associated BE. AECOPD with BE 
were older, had lower body mass index and greater functional impairment and severity of symptoms 
than AECOPD without BE. After PSM, 91 patients were considered for each group and no significant 
differences were found for all baseline characteristics. In full cohort, the cumulative mortality rate, the 
survival time, the Kaplan-Meier survival curves and the risk of death were worse in AECOPD with BE 
in the follow-up of 6-months, 1-year and 3-years. After PSM, data on mortality were similar between 
AECOPD with and without BE. In conclusion, in AECOPD patients the presence of BE does not influence 
mortality in a long-term follow-up.
Chronic Obstructive Pulmonary Disease (COPD) is a non-communicable disease representing the third cause of 
death worldwide1. During the natural course of COPD many patients experience acute exacerbation (AECOPD) 
characterized by a deterioration of respiratory signs and symptoms2 and an increase of inflammatory response3. 
Bronchiectasis (BE) is a chronic respiratory condition related to a dilatation of bronchi and airway wall thickening 
on imaging of chest computed tomography (CT) scan4; this irreversible alteration may lead to recurrent episodes 
of bronchial infections, inflammation, airway obstruction and progressive lung destruction5.
In order to define the risk stratification of COPD patients6, specific risk factors (age7, smoking8, sex9), clinical 
phenotypes (frequent exacerbators10, low body mass index-BMI11, increased dyspnoea12), and measurements of 
disease severity (forced expiratory volume in the 1st second-FEV113) are associated to worse prognosis. For this 
reason, these measured baseline characteristics (covariates) may be considered as predictors of mortality7–13.
At present, COPD is not considered a cause of BE and patients who fulfil both diagnostic criteria may be 
identified in an overlap condition14 having a prevalence between 27% and 69%4,15–18. Although the presence of 
BE has been reported as an unfavourable feature for COPD15,17,19–21, the role of the baseline covariates7–13 that 
are different between COPD patients with and without BE16,17,22 have been not entirely evaluated. Although 
the mortality risk of BE in COPD patients has been evaluated with regression adjustment15,17,18,20, residual con-
founding factors by unmeasured or inadequately measured baseline covariates may account for the rest of the 
risk. Comparability between groups should be a requirement in observational studies, avoiding indication bias, 
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a specific type of selection bias23; the use of restriction may minimize bias23,24. Propensity score (PS)25 repre-
sents the estimated probability of exposure assignment conditional on observed baseline covariates. Propensity 
score matching (PSM) matches patients in each group based on the similarity of their PS and the distribution 
of observed baseline covariates will be similar between exposed and unexposed subjects, reducing the effect of 
confounding variables26.
Our study hypothesis was that potential baseline covariates may influence the clinical impact and prognosis of 
hospitalized AECOPD patients with BE in a short and long-term follow-up. Using a PSM method and eliminating 
baseline differences between AECOPD patients with and without BE, we could evaluate the impact of BE that is 
still lacking in AECOPD patients.
Methods
Study Design. This was a prospective study conducted at the Hospital Clinic of Barcelona (Spain) in a period 
of 7 years between May 2009 and May 2016. The sampling method was systematic and all AECOPD patients 
admitted to our Pneumology Department were enrolled in the study.
Patients Selection. The patients included had to meet COPD criteria according to the GOLD document27. 
Spirometry was performed in the stable phase and at least six months prior admission to hospital and a smoking 
history of 20 pack/years was considered as a positive habit. Definition of AECOPD was based on worsening of 
respiratory symptoms compared with preceding days requiring a change in domiciliary therapy27; the hospital-
ization was based on the severity of AECOPD according to the respiratory signs or symptoms and the presence 
of potential indicators27.
The presence of BE was detected by a chest CT scan, performed during hospitalization or in a period of at least 
six months before hospital admission. The radiological features of BE collected regards type (cylindrical, cystic or 
both), distribution (upper, middle or lower lobes or associated lobes), position (lung right, left or bilateral), and 
extension (or ≥3 involved lobes). Patients without a chest CT scan available were classified as AECOPD without 
BE.
Exclusion Criteria. The exclusion criteria concerned patients with a documented history of other concomi-
tant chronic respiratory disease (asthma, cystic fibrosis) and patients in whom a community-acquired pneumonia 
or an acute heart failure were identified clinically and by chest X-ray or CT scan at admission.
Ethics statement. The Hospital’s Ethics Committee approved the study protocol (CEIC 2008/4106), con-
ducted according to the Good Clinical Practices and the declarations of Helsinki. An informed consent have been 
obtained from all enrolled patients.
Microbiological Sample collection. On the first day of hospitalization sputum sample was collected from 
spontaneous cough; if the sample was adequate (a count of more than 25 leukocytes and less than 10 epithelial 
cells per field) it was processed using Gram stain and sputum culture. In patients without a spontaneous sputum 
sample an induced sputum production was obtained by an inhalation of a 5% hypertonic saline solution for 5 to 
10 minutes delivered via a nebulizer device.
Measurements. Data about demographic variables, body mass index (BMI), smoking habit (current or for-
mer) with number of pack/year, number of comorbidities (Charlson index), prevalence of ischemic heart disease 
and diabetes, dyspnea grade measured by the modified Medical Research Council (mMRC) scale, severity of dis-
ease (COPD severity score measured by a COPD-SS questionnaire), and use of long-term oxygen therapy (LTOT) 
were recorded. Season of occurrence of AECOPD, characteristics and number of previous AECOPD occurring 
in the preceding year and data on home care medications (inhaled bronchodilators as short-acting β2 agonist 
[SABA], long-acting β2 agonist [LABA], anticholinergics, inhaled steroids [ICS]) were also recorded.
Vital signs (body temperature, respiratory and heart rate, systolic and diastolic blood pressure) were assessed 
at admission. At admission and at day 3 we recorded data about gas analysis (pH, partial arterial carbon dioxide 
pressure [PaCO2], the ratio of partial arterial oxygen pressure to the fraction of inspired oxygen [PaO2/FiO2], 
serum bicarbonate [HCO3−], and base excess [BE]), systemic response (leukocytes, haematocrit, haemoglobin, 
C-reactive protein [CRP], glucose, and creatinine). Data on number of patients using systemic corticosteroids 
and/or antibiotics, duration of antibiotic treatment and classes of antibiotics used were also recorded.
Outcomes. Length of hospital stay (LOS), use of non-invasive and invasive mechanical ventilation (NIMV 
and IMV), and intensive care unit (ICU) admission were considered as variables of clinical progression. Data on 
prognosis (cumulative number of deaths for all-causes, estimated time to death) were recorded in a follow-up of 
30 days, 6 months, 1 year and 3 years. The date of death was identified by centralized registries.
Statistical analysis. A total sample size of 182 patients (91 patients in the group of AECOPD with BE and 
91 patients in the group of AECOPD without BE, according to 1:1 allocation ratio) was estimated to provide at 
least a 80% power and a two-sided alpha value of 0.05 to detect as statistically significant an absolute difference 
of 15% in the percentage of 3-years mortality of patients between groups (20% patients with BE vs 5% patients 
without BE)17.
Data were reported with number and percentage of patients for categorical variables, means ± standard devi-
ation (SD) or medians [1st quartile; 3rd quartile] for continuous variables with normal and non-normal distribu-
tion, respectively. Categorical variables were compared using the X2 test or the Fisher exact test while continuous 
variables with the t test or the non-parametric Mann-Whitney test.
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PS was used to obtain the balance among baseline variables between AECOPD patients with and without BE 
listed in Table 1. A PSM program28 was used to match the two cohorts using a 1:1 nearest neighbour matching, 
without replacement within a caliper width of 0.2. Variables were chosen for inclusion in the PS calculation 
according to the methods of Brookhart et al.29 and included variables associated with hospitalized AECOPD 
patients with BE and outcome (age, BMI, FEV1, smoking habit, COPD-SS questionnaire, chest CT scan, and 
patients with ≥2 previous AECOPD). After matching, an adequate comparability was shown by a decrease to 
<20% (0.2) of the standardized mean difference30 between AECOPD with and without BE for all baseline covari-
ates (Fig. 1); moreover, an adequate model fit with discrimination and calibration of the PS was demonstrated by 
the logistic model including covariates yielded a Goodness-of-Fit p = 0.321.
Time-to event variables were analysed by means of Kaplan-Meier survival curves and a 
Gehan-Breslow-Wilcoxon test was applied because this test emphasizes early differences31. Patients lost to 
follow-up were censored in the survival analysis. Cox proportional hazard regression models were used in mor-
tality at 30-days, 6-months, 1-year, and 3-years32. The hazard ratio (HR) and its 95% confidence intervals (CI) 
were calculated.
All statistical analyses were performed using IBM SPSS Statistics 24.0 (Armonk, New York, USA). A value of 
p < 0.05 was considered statistically significant.
Variables
AECOPD (Full cohort)(n = 449)









BE(n = 91) p-value
Age, years 70.4 ± 10.2 72.7 ± 8.6 0.014 70.9 ± 9.4 71.3 ± 8.6 0.761
Male, % 79 84 0.183 82 85 0.689
BMI, kg/m2 27.8 ± 5.6 26.5 ± 4.9 0.022 27.4 ± 5.0 27.3 ± 5.1 0.887
Smoking habit: Current/Former,% 47/53 26/74 <0.001 35/65 30/70 0.428
Pack/year 60 [40; 80] 59.5 [40; 80] 0.917 60 [40; 80] 50 [40; 80] 0.430
FEV1,% predicted 48.5 ± 18.9 44.6 ± 17.2 0.040 46.2 ± 17.8 47.0 ± 17.7 0.758
FEV1/FVC 51.2 ± 14.6 48.0 ± 15.1 0.047 50.7 ± 14.2 48.9 ± 16.6 0.446
GOLD 2017 stages: A/B/C/D,% 31/37/12/21 17/33/16/33 0.017 22/36/19/22 21/36/18/24 0.991
LTOT, % 23 36 0.004 23 24 0.861
mMRC dyspnea grade 2 [1; 3] 2 [1; 3] 0.014 2 [1; 3] 2 [1; 3] 0.670
COPD-SS severity questionnaire 12 [7; 17.5] 16 [11; 20] <0.001 14 [9; 17] 14 [9; 18] 0.798
Charlson index 2 [1; 3] 2 [1; 3] 0.174 2 [1; 3] 2 [1; 4] 0.785
Ischemic heart disease, % 9 11 0.582 8 10 0.601
Diabetes, % 23 22 0.866 19 20 0.851
Season of admission:Winter/Spring/
Summer/Autumn, % 44/14/26/17 41/17/28/13 0.543 41/19/27/13 37/18/31/14 0.947
Previous AECOPD† 0 [0; 1] 1 [0; 2] 0.042 1 [0; 2] 0 [0; 1] 0.343
Patients with ≥2 previous AECOPD†, % 25 30 0.212 27 23 0.495
Previous AECOPD requiring 
hospitalization† 0 [0; 1] 0 [0; 1] 0.006 0 [0; 1] 0 [0; 1] 0.717
Patients with ≥1 previous AECOPD 
requiring hospitalization†, % 29 41 0.007 34 31 0.635
Patients having a chest CT scan#, % 73 100 <0.001 100 100 >0.999
Salbutamol only, % 5 1 0.090 2 0 0.497
Anticholinergic only, % 6 5 0.609 3 8 0.206
LABA+Anticholinergic, % 2 1 0.412 2 1 >0.999
LABA+ICS, % 3 2 0.747 2 4 0.678
Anticholinergic+ICS, % 1 3 0.437 1 1 >0.999
LABA+Anticholinergic+ICS, % 36 38 0.702 41 38 0.656
Table 1. Baseline characteristics of AECOPD patients evaluated in the full cohort and in the propensity 
score matching sample. Data are shown as number of patients (percentage), means ± standard deviation or 
medians [1st quartile; 3rd quartile], unless otherwise stated. Percentages are calculated on non-missing data. 
Abbreviations: AECOPD indicates acute exacerbation of COPD; BE, bronchiectasis; BMI, body mass index; 
FEV1, forced expiratory volume in the 1st second; FVC, forced vital capacity; GOLD, global initiative for chronic 
obstructive lung disease; LTOT, long-term oxygen therapy; mMRC, modified Medical Research Council; 
COPD-SS, COPD severity score questionnaire; LABA, long-acting β2 agonist; ICS, inhaled corticosteroids. 
LABA includes salmeterol, formoterol and indacaterol; Anticholinergic includes ipratropium and tiotropium; 
and ICS includes budesonide and fluticasone. *The variables included as covariates in the propensity score 
matching were: age, body mass index, forced expiratory volume in the 1st second; smoking habit, COPD-SS 
severity questionnaire, chest CT scan, and patients with ≥2 previous AECOPD. †Previous AECOPD were 
considered if occurring in a period of the preceding year. #The chest CT scan was obtained in a period of six 
months prior the hospitalization or during the hospitalization.
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Data availability. The datasets generated during and/or analysed during the current study are available from 
the corresponding author on reasonable request.
Results
Baseline characteristics. 449 consecutive AECOPD patients (81% men) with a mean age of 72 years were con-
sidered; of these, 160 patients (36%) had associated BE. The chest CT scan was available in 330 patients (73%); in the 
PSM sample only patients having a chest CT scan (n = 182) were considered. Figure 2 shows the study flow diagram.
In full cohort, AECOPD patients with BE were older, with a lower BMI and greater functional impairment, 
severity of symptoms and questionnaire-reported severity characteristics than AECOPD patients without BE. 
Moreover, patients with BE were more frequently former smokers, with need for LTOT and had a significant his-
tory of AECOPD in the previous year, also requiring hospitalization. After PSM, no significant differences were 
found in all baseline characteristics (see Table 1).
Concerning the radiological aspects of BE, the cylindrical type (circle A) with a distribution in the lower lobes 
(circle B), in a bilateral position (circle C) and involving ≤3 lobes (circle D) represent the most prevalent features 
(86%, 41%, 77%, and 61%, respectively) (Fig. 3).
Clinical, laboratory and microbiological variables. With regard to clinical and laboratory variables 
(Table 2), AECOPD patients with BE in comparison to patients without BE showed a higher C-reactive protein (CRP) 
level at day 3 (median 1.7 mg/dL vs 0.9 mg/dL, p = 0.026) in full cohort. In the PSM cohort, at admission lower levels 
of PaCO2 (42.1 mmHg vs 49.1 mmHg, p = 0.003), HCO3− (26 mmol/L vs 28 mmol/L, p = 0.001), BE (1.4 mmol/L vs 
2.7 mmol/L, p = 0.015) and glucose (117 mg/dL vs 129 mg/dL, p = 0.028) were shown in AECOPD patients with BE. 
The other clinical and laboratory variables presented similar values in the two groups in both full and PSM cohort.
In full cohort, a greater prevalence of Pseudomonas aeruginosa (38% vs 19%, p = 0.037) and a lower prevalence 
of Haemophilus influenzae (8% vs 24%, p = 0.049) were shown in AECOPD patients with BE in comparison to 
patients without BE; after matching, all microbiological variables were similar between groups (Table 3).
Outcomes. In the full cohort, AECOPD with BE in comparison to patients without BE showed a lower preva-
lence of NIMV (15% vs 25%, p = 0.011) and ICU admission (7% vs 15%, p = 0.016); the PSM cohort confirm data 
about lower prevalence of ICU admission in AECOPD with BE (6% vs 14%, p = 0.047) (Table 4).
In full cohort, the cumulative mortality rate was significantly higher in AECOPD patients with BE in com-
parison to patients without BE in the follow-up of 6-months, 1-year and 3-years (17% vs 9%, p = 0.015; 27% vs 
16%, p = 0.013; 51% vs 40%, p = 0.045; respectively). Moreover, the mean survival time was lower in AECOPD 
patients with BE (mean 163.9 days vs 170.5 days, p = 0.016 at 6-months; 304.2 days vs 328.1 days, p = 0.009 at 
1-year; 766.8 days vs 852.1 days, p = 0.014 at 3-years) (Table 4). The Kaplan-Meier survival curves (Fig. 4) showed 
an unfavourable role of AECOPD patients with BE (Gehan-Breslow-Wilcoxon test p = 0.011 in the follow-up of 
3 years). In the follow-up of 6-months, 1-year and 3-years, Cox regression (Table 5) showed an increased risk of 
death for all-causes in AECOPD patients with BE (HR [95% CI] 1.94 [1.12 to 3.36], p = 0.018; 1.73 [1.13 to 2.65], 
Figure 1. Plot displaying standardized mean differences in baseline characteristics between AECOPD patients 
without and with BE, before and after propensity score matching. Abbreviations: BE indicates bronchiectasis; 
BMI, body mass index; FEV1, forced expiratory volume in the 1st second; FVC, forced vital capacity; LTOT, 
long-term oxygen therapy; mMRC, modified Medical Research Council; COPD-SS, COPD severity score 
questionnaire; AECOPD acute exacerbation of COPD.
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p = 0.012; 1.39 [1.02 to 1.89], p = 0.036; respectively). After PSM, the mortality rate, the mean survival time, the 
Kaplan-Meier survival curves, and the risk of death were similar between AECOPD patients with and without BE 
(Table 4, Fig. 4 and Table 5, respectively).
Figure 2. Study flow chart. Abbreviations: AECOPD stands for acute exacerbation of COPD; BE, 
bronchiectasis.
Figure 3. Radiological features of AECOPD patients with BE. Circles A,B,C, and D show the number and 
percentage of patients according to the radiological features (type, distribution, position, and extension, 
respectively).
www.nature.com/scientificreports/
6SCIEnTIFIC REPORTS |  (2018) 8:9236  | DOI:10.1038/s41598-018-27680-y
Concerning the prevalence of radiological features of BE according to the outcomes (Fig. 5), the only right 
position in comparison to only left and bilateral was respectively associated to a higher prevalence of NIMV (37%, 
9% and 13%, p = 0.027) and survivors at 3-years (69%, 21% and 54%, p = 0.011). Data about type, distribution, 
and extension of BE had not influenced all outcomes.
In the comparison of baseline covariates between survivors and deaths (Table 6), in full cohort, in the follow-up 
of 6-months, 1-year and 3-years, deaths were among significantly older patients, former smokers, patients with 
greater staging severity, needing LTOT, with a higher dyspnoea grade, a greater questionnaire-reported severity 
and a higher number of previous AECOPD also needing hospitalization. BMI, FEV1% predicted and Charlson 
index were respectively worse in deaths at the follow-up of 1-year and 3-years, while prevalence of male gender 
were higher at 3-year follow-up only. In the PSM cohort, the Charlson index was different among survivors and 
death in the follow-up of 1-year and 3-years, while age, GOLD 2017 stage, LTOT, mMRC, and COPD-SS ques-
tionnaire were different in the follow-up of 3-years.
Variables
AECOPD (Full cohort) AECOPD (Propensity score matching)
Without BE With BE p-value Without BE With BE p-value
Respiratory rate at admission, b/min 24 [20; 28] 24 [20; 28] 0.716 23 [20; 26] 24 [20; 28] 0.544
Heart rate at admission, b/min 92 [81; 104] 94 [84; 108] 0.199 90 [81; 100] 91 [83; 108] 0.329
Body temperature at admission, °C 36.4 [36; 36.9] 36.3 [35.9; 36.9] 0.760 36.2 [35.9; 36.7] 36.3 [35.7; 36.9] 0.841
SBP at admission, mmHg 138 [120; 156] 139 [124; 155] 0.531 137 [119; 152] 143 [122; 157] 0.156
DBP at admission, mmHg 75.5 [67; 87] 76 [69; 86] 0.780 76 [68; 86] 79 [69; 87] 0.574
pH at admission 7.39 [7.33; 7.43] 7.39 [7.36; 7.43] 0.112 7.39 [7.33; 7.44] 7.41 [7.37; 7.44] 0.081
- at day 3 7.41[7.39; 7.44] 7.40 [7.37; 7.43] 0.061 7.41 [7.38; 7.45] 7.40 [7.36; 7.43] 0.334
PaCO2 at admission, mmHg 48.8 [39.4; 61.4] 45.9 [37.4; 56.5] 0.136 49.1 [40.4; 57.9] 42.1 [36.7; 50.8] 0.003
- at day 3 46.6 [41.2; 53.5] 49.5 [41.7; 55.9] 0.461 46 [39; 54.4] 48.5 [42.3; 53.3] 0.582
PaO2/FiO2 at admission, mmHg 262 [215; 318] 259 [225; 314] 0.855 260 [206; 315] 259 [228; 334] 0.476
- at day 3 286 [252; 316] 279 [253; 314] 0.885 287 [250; 331] 279 [250; 319] 0.601
HCO3 at admission, mmol/L 28 [25; 33] 28 [24; 31] 0.112 28 [26; 32] 26 [23; 29] 0.001
- at day 3 30 [26; 33] 30 [27; 32] 0.746 31 [26; 35] 28 [27; 30] 0.344
BE at admission, mmol/L 2.4 [0.1; 6] 2.2 [−0.4; 5.2] 0.400 2.7 [0.6; 5.9] 1.4 [−0.8; 3.7] 0.015
- at day 3 4.4 [2.0; 7.4] 4.2 [1.5; 6.7] 0.808 4.4 [0.1; 7.4] 3.4 [1.3; 5.8] 0.880
Leucocytes at admission, x 109/l 10.1 [7.7; 13.8] 10.2 [8; 14] 0.586 10.1 [7.3; 13.8] 10.7 [8.5; 14.1] 0.167
- at day 3 10.9 [8.3; 12.9] 10.5 [8.2; 13.5] 0.800 10.6 [7.9; 12.3] 10.3 [8.5; 13.4] 0.365
Haematocrit at admission,% 43 [40; 47] 43 [39; 47] 0.445 43 [39; 47] 44 [40; 48] 0.330
- at day 3 41 [37; 45] 40 [37; 44] 0.330 41 [37; 44] 42 [37; 45] 0.916
Haemoglobin at admission, g/L 140 [127; 152] 137 [124; 151] 0.339 138 [126; 151] 143 [126; 154] 0.319
- at day 3 132 [119; 143] 129 [115; 143] 0.270 134 [118; 144] 136 [118; 146] >0.999
C-reactive protein at admission, mg/dL 3.7 [1.1; 9.5] 3.7 [1.5; 10.5] 0.316 4.0 [1.4; 9.4] 3.2 [1.5; 7.6] 0.764
- at day 3 0.9 [0.3; 2.9] 1.7 [0.4; 4.7] 0.026 0.9 [0.4; 3.1] 1.6 [0.3; 4.2] 0.330
Glucose at admission, mg/dL 126 [109; 161] 122 [104; 159] 0.192 129 [113; 165] 117 [103; 150] 0.028
- at day 3 122 [98; 159] 119 [96; 151] 0.426 127 [101; 155] 116 [95; 149] 0.337
Creatinine at admission, mg/dL 0.9 [0.8; 1.1] 0.9 [0.8; 1.1] 0.278 0.9 [0.8; 1.1] 1.0 [0.8; 1.1] 0.968
- at day 3 0.8 [0.7; 1.1] 0.9 [0.8; 1.1] 0.056 0.9 [0.7; 1.2] 0.9 [0.8; 1.1] 0.329
Patients using systemic corticosteroids, % 90 94 0.211 89 93 0.284
Patients using antibiotics, % 85 89 0.155 87 94 0.115
Duration of antibiotic treatment, days 7 [5.5; 10] 7 [5; 10] 0.791 7 [5; 9] 7 [5; 10] 0.383
Penicillins, % 18 16 0.779 9 14 0.293
Fluoroquinolones, % 50 52 0.731 48 56 0.333
Macrolides, % 2 1 >0.999 0 1 >0.999
Cefalosporins, % 5 1 0.144 4 0 0.103
Carbapenems, % 1 0 0.532 1 0 0.473
Table 2. Clinical and laboratory variables recorded at admission and at day 3. Data are shown as number 
of patients (percentage), means ± standard deviation or medians [1st quartile; 3rd quartile], unless otherwise 
stated. Percentages are calculated on non-missing data. Abbreviations: AECOPD indicates acute exacerbation 
of COPD; BE, bronchiectasis; SBP and DBP, systolic and diastolic blood pressure, respectively; PaCO2, partial 
arterial carbon dioxide pressure; PaO2/FiO2, ratio of partial arterial oxygen pressure to the fraction of inspired 
oxygen; HCO3−, serum bicarbonate; BE, base excess. Systemic corticosteroids include methylprednisolone; 
Penicillins includes amoxicillin and amoxicillin/clavulanate; Fluoroquinolones includes ciprofloxacin, 
moxifloxacin, and levofloxacin; Macrolides includes azithromycin and clarithromycin; Cefalosporins includes 
ceftriaxone, cefotaxime, cefuroxime and cefepime; and Carbapenems includes meropenem.
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Discussion
The coexistence of both COPD and BE has been recently defined as an emerging phenotype of patients14 who 
experience worse prognosis15,17,19–21; however, data on these patients do not consider several baseline covariates 
as cofounders. Our prospective study, performed for the first time in hospitalized AECOPD patients and using a 
PSM method, demonstrated that the presence of BE does not worse the clinical impact at admission, the clinical 
progression, the rate and the risk of short and long-term mortality.
Prevalence and characteristics associated to BE. Although in literature a large prevalence of BE asso-
ciated to COPD is reported4,15–18, our prevalence in AECOPD patients was slight higher (36% vs 27%) in com-
parison with COPD patients in whom a CT scan was performed to phenotype the heterogeneity of disease4. 
Recent data on distinctive clinical, functional and microbiological phenotypes of patients with BE have shown 
the prevalence of BE having COPD as the aetiology cause in a percentage of 11%33, lower than previous reports 
(17%)34. It is than clear that differences in prevalence of patients having COPD and BE depend on the respective 
population under consideration.
Baseline characteristics of our patients with BE were consistent with other reports on age15,17, low BMI15–17, 
smoking habit15, severe obstruction16,17,22, greater dyspnoea16,17, need for oxygen-therapy17,22 and previous exacer-
bation events16,17,22. Concerning our higher prevalence of Pseudomonas aeruginosa isolation in patients AECOPD 
with BE, previous studies on COPD in stable phase confirmed these data4,16–18,22. The presence of this pathogen, 
most frequently in severe patients and during exacerbations35, favours the hypothesis that potentially pathogenic 
microorganisms (PPM) - and Pseudomonas aeruginosa is one of the most important PPM - are responsible for the 
development of BE by an increase in chronic inflammation36. Surprisingly, the prevalence of Haemophilus influ-
enzae in our cohort with a positive sputum culture (n = 16, 17%) was lower in comparison to AECOPD patients 
in general37, to BE patients38, and stable COPD patients17. However, this prevalence was similar after PSM (n = 6, 
15%) with a similar trend between AECOPD patients with and without BE. A different pathogen detection or a 
previous use of antibiotics before admission (not collected in this study) may explain the difference in prevalence.
Clinical impact of BE at admission. To our knowledge, we have reported for the first time data on the 
impact of BE on clinical presentation of AECOPD patients. In clinical practice, it is common belief that BE 
patients especially if in association with an AECOPD may have a worse impact. However, our findings demon-
strate that clinical and laboratory data of AECOPD with and without BE were similar, except for hypercapnia 
levels with renal compensation, that appear better in AECOPD with BE, as well the prevalence of ICU admission 
(Tables 2 and 4). Interestingly, also the early inflammatory profile of AECOPD with and without BE was similar. 
Although COPD patients may have different profiles in response to pneumonic and nonpneumonic exacerba-
tions39, we demonstrated that the presence of BE in AECOPD does not induce a stronger early inflammatory 
response.
AECOPD (Full cohort)










Patients with positive cultures 
in sputum* 53 (18) 39 (24) 0.150 18 (20) 23 (25) 0.442
Pseudomonas aeruginosa 10 (19) 15 (38) 0.037 5 (28) 7 (30) 0.853
Haemophilus influenzae 13 (24) 3 (8) 0.049 5 (28) 1 (4) 0.070
Streptococcus pneumoniae 10 (19) 8 (20) 0.844 3 (17) 7 (30) 0.467
Staphylococcus spp 5 (9) 2 (5) 0.695 2 (11) 1 (4) 0.573
Pasteurella 0 (0) 2 (5) 0.177 0 (0) 1 (4) >0.999
Moraxella catarrhalis 3 (6) 0 (0) 0.259 0 (0) 0 (0) —
Candida spp 1 (2) 1 (3) >0.999 0 (0) 1 (4) >0.999
Aspergillus 0 (0) 2 (5) 0.177 0 (0) 1 (4) >0.999
Serratia 1 (2) 0 (0) >0.999 0 (0) 0 (0) —
Mycobacterium no-TBC 0 (0) 1 (3) 0.424 0 (0) 1 (4) >0.999
Polymicrobial etiology 10 (18) 5 (13) 0.508 3 (17) 3 (13) >0.999
Virus-positive patients* 15 (5) 7 (4) 0.714 5 (5) 4 (4) >0.999
Influenza B virus 1 (7) 1 (14) >0.999 0 (0) 0 (0) —
Respiratory syncytial virus 6 (40) 1 (14) 0.430 1 (20) 0 (0) >0.999
Rhinovirus 4 (27) 3 (43) 0.704 1 (20) 2 (50) >0.999
Parainfluenza virus type 1 2 (13) 1 (14) >0.999 1 (20) 1 (25) >0.999
Parainfluenza virus type 3 2 (13) 0 (0) 0.540 2 (40) 0 (0) 0.497
Parainfluenza virus type 4 0 (0) 1 (14) 0.356 0 (0) 1 (25) >0.999
Table 3. Microbiological variables. Data are shown as number of patients (percentage). *The percentages 
are related to the number of patients without and with BE. The percentages of pathogens are related in each 
group to the number of patients with positive cultures in sputum or a virus-positivity. Abbreviations: AECOPD 
indicates acute exacerbation of COPD; BE, bronchiectasis.
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Mortality related to BE. In patients with AECOPD several predictors of mortality have been identified in a 
short and long-term period40; as well in our data (Table 6), age, BMI, FEV1, and LTOT predict the worse prognosis 
of AECOPD40.
There are no published studies evaluating the risk of death based on the presence of BE during an AECOPD, 
while in COPD patients the association with BE have been reported with15,17,19,20 and without18 an impact on 
mortality. However, studies reporting the worse prognosis, also considered for a recent meta-analysis21, concern 
preliminary data with very few enrolled patients19 and studies considering patients with evident baseline covar-
iates, including elderly patients20, patients with very severe lung functional impairment19,20, and patients with 
chronic respiratory failure needing oxygen-therapy20. Moreover, the adjustments in regression analysis leading 
to more striking estimates supported the hypothesis that confounding cannot account for the result15; the role of 
confounding should always be considered as a possible alternative storyline41.
Variables
AECOPD (Full cohort) AECOPD (Propensity score matching)
Without BE With BE p-value Without BE With BE p-value
LOS, days 8 [6; 11] 8 [6; 10] 0.864 8 [6; 12] 7 [6; 10] 0.290
NIMV, % 25 15 0.011 23 13 0.077
IMV, % 4 4 0.830 2 3 >0.999
ICU admission, % 15 7 0.016 14 6 0.047
30-days mortality, 
n (%) 7 (2) 5 (3) 0.762 0 (0) 1 (1) >0.999
Survival time 29.5 [29.2 to 29.9]
29.7 
[29.3 to 30.0] 0.668 — — —
6-months mortality, 
n (%) 25 (9) 26 (17) 0.015 4 (5) 4 (5) >0.999
Survival time 170.5[166.6 to 174.4]
163.9




[170.6 to 179.9] 0.991
1-year mortality, 
n (%) 44 (16) 40 (27) 0.013 8 (10) 10 (12) 0.781
Survival time 328.1[318.2 to 338]
304.2




[325.3 to 352.8] 0.688
3-years mortality, 
n (%) 95 (40) 71 (51) 0.045 26 (36) 26 (34) 0.764
Survival time 852.1[810.3 to 894]
766.8




[853.7 to 986.1] 0.762
Table 4. Study outcomes. Data are shown as number of patients (percentage) or medians [1st quartile; 3rd 
quartile], unless otherwise stated. Percentages are calculated on non-missing data. Data for mortality was 
reported as cumulative. Data for survival time was calculated as mean [95% confidence interval] and reported 
as days. Abbreviations: AECOPD indicates acute exacerbation of COPD; BE, bronchiectasis; LOS, length of stay 
in hospital; NIMV and IMV, noninvasive and invasive mechanical ventilation, respectively; ICU, intensive care 
unit. In the propensity score matching group the survival time for 30-days mortality was not computed because 
all cases are censored. There is only one valid survival function value per group in at least one stratum.
Figure 4. Kaplan-Meier survival curves in the follow-up period of 3-years in full cohort and in the propensity 
score matching cohort. Abbreviations: AECOPD stands for acute exacerbation of COPD; BE, bronchiectasis.
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Why a PSM method for our observational data: a comparison with regression adjustment. 
Historically, regression adjustment has been used more frequently than PS methods to account for differences in 
measured baseline characteristics between exposed and unexposed subjects. However, there are several reasons 
for preferring PS-based methods to regression-based methods for reducing the effects of confounding in obser-
vational studies.
First, related to the occurrence of BE and baseline covariates to the outcome, it is simpler to determine 
whether the PS model rather the regression model has been adequately specified. Diagnostics for PS are based 
on comparing the distribution of measured baseline covariates, between AECOPD with and without BE in the 
PSM sample. Goodness-of-fit measures in regression models do not provide a test of whether the outcome model 
has been correctly specified. Furthermore, goodness-of-fit do not allow one to determine the degree to which the 
fitted regression model has successfully eliminated systematic differences between AECOPD patients with and 
without BE.
Second, similarly to a randomized controlled trial (RCT), the PS-based methods allow one to separate the 
design from the analysis of the study, without any reference to the outcome. However, when using regression 
adjustment, the outcome is always in sight, and the researcher is faced with the subtle temptation to continually 
modify the regression model until the desired association has been achieved42.
HR 95% CI p-value
30-days mortality
   Crude (full cohort) 1.28 0.40 to 4.04 0.669
   Propensity score matching — — —
6-months mortality
   Crude (full cohort) 1.94 1.12 to 3.36 0.018
   Propensity score matching 0.97 0.24 to 3.91 0.977
1-year mortality
   Crude (full cohort) 1.73 1.13 to 2.65 0.012
   Propensity score matching 1.14 0.45 to 2.90 0.771
3-years mortality
   Crude (full cohort) 1.39 1.02 to 1.89 0.036
   Propensity score matching 0.91 0.53 to 1.58 0.760
Table 5. Cox regression models evaluating the risk of all-causes death for AECOPD with BE. Abbreviations: 
AECOPD indicates acute exacerbation of COPD; BE, bronchiectasis; HR, hazard ratio; CI, confidence interval. 
Cox regression for 30-days mortality in the propensity score matching sample cannot compute because all cases 
are censored.
Figure 5. Prevalence of radiological features of AECOPD patients with BE according to the outcomes. 
Abbreviations: NIMV stands for non-invasive mechanical ventilation.
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Third, there may be increased flexibility when the occurrence of BE is more common than outcome 
(time-to-event in nature)43. When outcome is time-to-event in nature, prior research has suggested that at least 10 
events should be observed for every covariate that is entered into a regression model44,45. Thus, in some settings, 
insufficient outcomes may be observed to allow one to adequately adjust for all baseline variables that one would 
like to include in the regression model.
Fourth, the PS method provides a better assessment of the degree of overlap between the distribution of base-
line covariates, comparing the outcome between patients who have a similar distribution of observed baseline 
covariates. In a setting in which there is a strong separation between the two groups, the analyst may proceed 
with a regression-based analysis without being aware that the fitted regression model is interpolating between 
two distinct populations.
In conclusion, PS method allows one to transparently design and analyze our observational study.
Variables
6-months 1-year 3-years
Survivors Deaths p-value Survivors Deaths p-value Survivors Deaths p-value
Age, years 70.6 ± 9.8 76.9 ± 7.3 <0.001 70.5 ± 9.7 75.2 ± 8.6 <0.001 69.4 ± 10.1 75.0 ± 8.2 <0.001
Propensity score matching 70.9 ± 9.0 76.8 ± 7.2 0.067 71.3 ± 8.8 71.8 ± 9.2 0.831 70.3 ± 9.4 73.7 ± 7.4 0.018
Male, % 81 90 0.120 82 89 0.096 80 92 0.002
Propensity score matching 85 75 0.350 86 89 >0.999 86 92 0.229
BMI, kg/m2 27.4 ± 5.5 26.6 ± 4.2 0.451 27.7 ± 5.4 25.6 ± 4.7 0.009 28.2 ± 5.6 25.9 ± 4.6 <0.001
Propensity score matching 27.3 ± 5.1 28.4 ± 4.1 0.535 27.4 ± 5.1 27.6 ± 4.4 0.878 27.8 ± 5.4 26.9 ± 4.3 0.315
Smoking habit: Current/Former, % 42/58 16/84 <0.001 44/56 19/81 <0.001 46/54 22/78 <0.001
Propensity score matching 33/67 13/87 0.439 31/69 33/67 0.858 34/66 23/77 0.165
FEV1,% predicted 47.4 ± 18.6 42.9 ± 16.8 0.150 47.8 ± 18.2 42.7 ± 17.4 0.034 48.9 ± 17.8 41.8 ± 16.1 <0.001
Propensity score matching 46.3 ± 17.8 49.6 ± 16.3 0.613 46.7 ± 17.5 47.2 ± 18.7 0.911 47.3 ± 17.0 43.3 ± 16.4 0.170
GOLD 2017 stages: A/B/C/D,% 28/37/15/20 5/17/0/78 <0.001 30/39/15/16 10/26/0/64 <0.001 30/42/16/12 12/38/7/43 <0.001
Propensity score matching 24/36/19/21 0/0/0/100 0.292 25/37/20/18 25/25/0/50 0.132 27/38/22/13 19/34/9/38 0.021
LTOT, % 22 65 <0.001 19 57 <0.001 13 48 <0.001
Propensity score matching 23 25 >0.999 21 22 >0.999 13 35 0.002
mMRC dyspnea grade 2 [1; 3] 3 [2; 4] <0.001 2 [1; 3] 3 [2; 3] <0.001 2 [1; 3] 3 [2; 3] <0.001
Propensity score matching 2 [1; 3] 2 [1; 4] 0.864 2 [1; 3] 2 [1.2; 2.7] 0.845 2 [1; 3] 2 [1; 3] 0.013
COPD-SS severity questionnaire 13 [8; 18] 19 [16; 22] <0.001 12 [8; 17] 19 [14; 22] <0.001 11 [7.2; 16] 17 [12; 21] <0.001
Propensity score matching 14 [9; 18] 15 [8; 19] 0.631 13 [9; 16.7] 15 [10; 20] 0.115 12 [8; 16] 15 [12; 20] <0.001
Charlson index 2 [1; 3] 2 [1; 3] 0.305 2 [1; 3] 2 [1; 4] 0.011 2 [1; 3] 2 [1; 4] 0.001
Propensity score matching 2 [1; 3] 2 [1; 3.7] 0.960 2 [1; 3] 3.5 [1; 4.2] 0.015 2 [1; 3] 3 [1; 4] 0.017
Previous AECOPD 0 [0; 1] 1 [0; 3] 0.001 0 [0; 1] 1 [0; 3] <0.001 0 [0; 1] 1 [0; 2] <0.001
Propensity score matching 0 [0; 1] 0.5 [0; 1.7] 0.916 0 [0; 1] 1 [0; 1.2] 0.471 0 [0; 1] 1 [0; 1.7] 0.166
Patients with >2 previous AECOPD, % 23 47 <0.001 20 44 <0.001 16 34 <0.001
Propensity score matching 23 25 >0.999 21 22 >0.999 17 25 0.278
Previous AECOPD requiring 
hospitalization 0 [0; 1] 1 [0; 2] 0.001 0 [0; 1] 1 [0; 2] 0.155 0 [0; 0] 0 [0; 1] <0.001
Propensity score matching 0 [0; 1] 1 [0; 2] 0.779 0 [0; 1] 1 [0; 1] 0.001 0 [0; 1] 0 [0; 1] 0.125
Patients with ≥1 previous AECOPD 
requiring hospitalization, % 30 51 0.002 26 54 <0.001 24 45 <0.001
Propensity score matching 31 25 >0.999 28 44 0.144 26 38 0.108
Table 6. Comparison of baseline covariates between survivors and deaths, in the full cohort and in the 
propensity score matching sample, in the follow-up of 6-months, 1-year and 3-years. Data are shown as number 
of patients (percentage), means ± standard deviation or medians [1st quartile; 3rd quartile], unless otherwise 
stated. Percentages are calculated on non-missing data. For the full cohort data are calculated on survivors 
(n = 381, n = 333, and n = 208) and deaths (n = 51, n = 84 and n = 166) in the follow-up of 6-months, 1-year 
and 3-years, respectively. In the propensity score matching sample data are calculated on survivors (n = 163, 
n = 144, and n = 97) and deaths (n = 8, n = 18 and n = 52) in the follow-up of 6-months, 1-year and 3-years, 
respectively. In full cohort, the percentage of lost in AECOPD without and with BE groups was 4% and 4% 
(p > 0.999), 8% and 6% (p = 0.591), and 19% and 13% (p = 0.130) in the follow-up of 6-months, 1-year and 
3-years, respectively. In the propensity score matching sample, the percentage of lost in AECOPD without 
and with BE groups was 8% and 4% (p = 0.536), 15% and 7% (p = 0.058), and 21% and 15% (p = 0.336) in the 
follow-up of 6-months, 1-year and 3-years, respectively. Abbreviations: BMI indicates body mass index; FEV1, 
forced expiratory volume in the 1st second; GOLD, global initiative for chronic obstructive lung disease; LTOT, 
long-term oxygen therapy; mMRC, modified Medical Research Council; COPD-SS, COPD severity score 
questionnaire.
www.nature.com/scientificreports/
1 1SCIEnTIFIC REPORTS |  (2018) 8:9236  | DOI:10.1038/s41598-018-27680-y
Strength and limitation. The originality of using data about AECOPD patients with BE, the prospective 
and consecutive nature of the data collection, the large cohort of the patients enrolled, the long-term follow-up, 
and the statistical method using a PSM are the major strengths of our research. There are however some limita-
tions. First, our study was conducted at a single centre and in only one country; data from international centres 
are therefore necessary to confirm our findings. Second, we had not chest CT scans for all enrolled patients 
and we cannot exclude an under estimation of BE. However, in clinical practice at admission to hospital, in 
an AECOPD patient without a radiological (all patients enrolled had performed a chest X-ray) and a clinical 
suspicion of BE, the chest CT scan is not performed. We may reasonable hypothesize that really these patients 
were AECOPD without BE, as we have classified. Moreover, the presence of a chest CT scan has been used as a 
covariate for the PS model and then all patients considered in PSM cohort (with and without BE) had performed 
a chest CT scan; this have eliminated the hypothetical bias that patients performing a chest CT scan were worst 
patients. Finally, the analysis of data excluding patients without a chest CT scan in full cohort (data not shown), 
after matching of all baseline characteristics produce similar results; however, the total sample size was not ade-
quate to demonstrate the study hypothesis (see statistical analysis). Third, we lack information about the cause of 
death; in COPD patients, however, the causes of death (respiratory, cardiovascular, others) are not significantly 
influenced by BE17.
In conclusion, our study supports the hypothesis that in AECOPD patients, the clinical impact and prognosis 
of BE is influenced by several baseline covariates. After matching, with the elimination of confounding, BE does 
not directly worsen the prognosis of patients in a period until 3-years.
References
 1. Lozano, R. et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for 
the Global Burden of Disease Study 2010. Lancet. 380, 2095–128 (2012).
 2. Pavord, I.D., Jones, P.W., Burgel, P.R., Rabe, K.F. Exacerbations of COPD. Int J Chron Obstruct Pulmon Dis. 11 Spec Iss 21-30 (2016).
 3. Hurst, J. R. et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 
174, 867–874 (2006).
 4. Bafadhel, M. et al. The role of CT scanning in multidimensional phenotyping of COPD. Chest. 140, 634–642 (2011).
 5. Pasteur, M. C., Bilton, D. & Hill, A. T. British Thoracic Society Bronchiectasis non-CF Guideline Group. British Thoracic Society 
guideline for non-CF bronchiectasis. Thorax. 65(Suppl 1), i1–58 (2010).
 6. Agustí, A. & Celli, B. Avoiding confusion in COPD: from risk factors to phenotypes to measures of disease characterisation. Eur 
Respir J. 38, 749–51 (2011).
 7. Puhan, M. A. et al. Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated 
BODE index and the ADO index. Lancet. 374, 704–711 (2009).
 8. Kohansal, R. et al. The natural history of chronic airflow obstruction revisited: an analysis of the Framingham Offspring Cohort. Am 
J Respir Crit Care Med. 180, 3–10 (2009).
 9. De Torres, J. P. et al. Sex differences in mortality in patients with COPD. Eur Respir J. 33, 528–535 (2009).
 10. Hurst, J. R. et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 363, 1128–1138 (2010).
 11. Schols, A. M., Broekhuizen, R., Weling-Scheepers, C. A. & Wouters, E. F. Body composition and mortality in chronic obstructive 
pulmonary disease. Am J Clin Nutr. 82, 53–59 (2005).
 12. Nishimura, K., Izumi, T., Tsukino, M. & Oga, T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients 
with COPD. Chest. 121, 1434–1440 (2002).
 13. Menezes, A. M. et al. FEV1 is a better predictor of mortality than FVC: the PLATINO cohort study. Plos One. 9, e109732 (2014).
 14. Hurst, J. R., Elborn, J. S. & De Soyza, A. BRONCH-UK Consortium. COPD-bronchiectasis overlap syndrome. Eur Respir J. 45, 
310–313 (2015).
 15. Mao, B. et al. The existence of bronchiectasis predicts worse prognosis in patients with COPD. Sci Rep. 5, 10961 (2015).
 16. Jin, J. et al. Factors associated with bronchiectasis in patients with moderate-severe chronic obstructive pulmonary disease. Medicine 
(Baltimore). 95, e4219 (2016).
 17. Martínez-García, M. A. et al. Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary 
disease. Am J Respir Crit Care Med. 187, 823–831 (2013).
 18. Gatheral, T. et al. COPD-related bronchiectasis; independent impact on disease course and outcomes. COPD. 11, 605–614 (2014).
 19. Sadigov, A. S. & Akhundov, S. Bronchiectasis associated with COPD: does it increase the mortality rate in patients with severe 
disease? [abstract]. Am J Respir Crit Care Med. 189, A6257 (2014).
 20. Katsura, H., Ogata, M. & Kida, K. Factors determining outcome in elderly patients with severe COPD on long-term domiciliary 
oxygen therapy. Monaldi Arch Chest Dis. 56, 195–201 (2001).
 21. Du, Q., Jin, J., Liu, X. & Sun, Y. Bronchiectasis as a Comorbidity of Chronic Obstructive Pulmonary Disease: A Systematic Review 
and Meta-Analysis. Plos One. 11, e0150532 (2016).
 22. Martínez-García, M. Á. et al. Factors associated with bronchiectasis in patients with COPD. Chest. 140, 1130–1137 (2011).
 23. Psaty, B. M. & Siscovick, D. S. Minimizing bias due to confounding by indication in comparative effectiveness research: the 
importance of restriction. JAMA 304, 897–898 (2010).
 24. Psaty, B. M. et al. Assessment and control for confounding by indication in observational studies. J Am Geriatr Soc. 47, 749–754 
(1999).
 25. Rosenbaum, P. R. & Rubin, D. B. The central role of the propensity score in observational studies for causal effects. Biometrika. 70, 
41–55 (1983).
 26. Austin, P. C. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. 
Multivariate Behav Res. 46, 399–424 (2011).
 27. Vogelmeier, C. F. et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 
Report: GOLD Executive Summary. Am J Respir Crit Care Med. 195, 557–582 (2017).
 28. Thoemmes, F. Propensity score matching in SPSS. arXiv:1201.6385 [stat. AP]. 2012.
 29. Brookhart, M. A. et al. Variable selection for propensity score models. Am J Epidemiol. 163, 1149–1156 (2006).
 30. Ho, D. E. et al. Matching as nonparametric preprocessing for reducing model dependence in parametric causal inference. Political 
Analysis. 15, 199–236 (2007).
 31. Mike, V., Stanley, K.E. eds. Statistics in medical research: methods and issues, with applications in cancer research. NY, USA: Wiley, 
1982.
 32. Collett, D. Modelling survival data in medical research. London: Chapman and Hall, 1994.
 33. Aliberti, S. et al. Clinical phenotypes in adult patients with bronchiectasis. Eur Respir J. 47, 1113–1122 (2016).
 34. Goeminne, P. C., Nawrot, T. S., Ruttens, D., Seys, S. & Dupont, L. J. Mortality in non-cystic fibrosis bronchiectasis: a prospective 
cohort analysis. Respir Med. 108, 287–296 (2014).
www.nature.com/scientificreports/
1 2SCIEnTIFIC REPORTS |  (2018) 8:9236  | DOI:10.1038/s41598-018-27680-y
 35. Patel, I. S. et al. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. 
Thorax. 57, 759–764 (2002).
 36. Cole, P. J. Inflammation: a two-edged sword–the model of bronchiectasis. Eur J Respir Dis Suppl. 147, 6–15 (1986).
 37. Wilkinson, T. M. A. et al. A prospective, observational cohort study of the seasonal dynamics of airway pathogens in the aetiology 
of exacerbations in COPD. Thorax. 72, 919–927 (2017).
 38. King, P. T., Holdsworth, S. R., Freezer, N. J., Villanueva, E. & Holmes, P. W. Microbiologic follow-up study in adult bronchiectasis. 
Respir Med. 101, 1633–1638 (2007).
 39. Huerta, A. et al. Pneumonic and nonpneumonic exacerbations of COPD: inflammatory response and clinical characteristics. Chest. 
144, 1134–1142 (2013).
 40. Singanayagam, A., Schembri, S. & Chalmers, J. D. Predictors of mortality in hospitalized adults with acute exacerbation of chronic 
obstructive pulmonary disease. Ann Am Thorac Soc. 10, 81–89 (2013).
 41. Walker, A. M. & Stampfer, M. J. Observational studies of drug safety (editorial). Lancet. 348, 489 (1996).
 42. Rubin, D. B. Using propensity scores to help design observational studies: Application to the tobacco litigation. Health Services & 
Outcomes Research Methodology. 2, 169–188 (2001).
 43. Braitman, L. E. & Rosenbaum, P. R. Rare outcomes, common treatments: Analytic strategies using propensity scores. Ann Intern 
Med. 137, 693–695 (2002).
 44. Peduzzi, P., Concato, J., Feinstein, A. R. & Holford, T. R. Importance of events per independent variable in proportional hazards 
regression analysis. II. Accuracy and precision of regression estimates. J Clin Epidemiol. 48, 1503–1510 (1995).
 45. Peduzzi, P., Concato, J., Kemper, J., Holford, T. R. & Feinstein, A. R. A simulation study of the number of events per variable in 
logistic regression analysis. J Clin Epidemiol. 49, 1373–1379 (1996).
Acknowledgements
This work was not supported by any financial source.
Author Contributions
Conception or design of the work E.C., M.G., A.I., A.G., N.S., A.C., A.T. Acquisition, analysis, or interpretation 
of data for the work E.C., M.G., A.I., A.C., A.H., A.G., N.S., A.C., A.T. Drafting the work or revising it critically 
for important intellectual content E.C., M.G., A.I., A.G., A.C., A.T. Final approval of the version submitted for 
publication A.T. Accountability for all aspects of the work in ensuring that questions related to the accuracy or 
integrity of any part of the work are appropriately investigated and resolved E.C., A.C., A.T.
Additional Information
Competing Interests: The authors declare no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2018
